预约演示
更新于：2025-04-25
Furosemide
呋塞米
更新于：2025-04-25
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [23] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
342
项与 呋塞米 相关的临床试验NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
NCT06821594
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.
ISRCTN16516753
Effect of Nebulized Furosemide on Mortality of Adult Mechanically Ventilated ARDS Patients. Protocol of a Randomized Clinical Trial (ENHALE Trial)
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
22,562
项与 呋塞米 相关的文献（医药）2025-08-01ARCHIVES OF INSECT BIOCHEMISTRY AND PHYSIOLOGY
Water Transport and Enzyme Recycling in Tenebrio molitor Midgut: Insights From Transcriptomics, Proteomics, and In Vivo Inhibition Assays
Article
作者: Terra, Walter R. ; Barroso, Ignacio G. ; Ferreira, Clelia
ABSTRACT:
The low excretory rates of secreted digestive enzymes, such as trypsins, in insect species with peritrophic membranes led to the hypothesis of ectoperitrophic countercurrent water fluxes causing enzyme recycling. The midgut water flux model of Tenebrio molitor (T. molitor) is revisited and supported by in vivo experiments. Sequences from proteins putatively involved in water transport were retrieved from the T. molitor transcriptome by Blast and analyzed using bioinformatics tools. Gene expression of selected proteins was determined in three midgut sections (anterior, AM; middle, MM; posterior, PM) by RNA‐seq, and transporter proteins were verified in microvillar‐membrane‐enriched midgut samples by proteomics. Genes encoding three cation chloride cotransporters (CCC) and four aquaporins were expressed in the midgut. TmNaCCC2, TmPrip, and TmEglp1 showed higher expression in the front half, while TmKCC, TmNKCC1, TmDrip, and TmEglp2 were more highly expressed in the back half. However, only TmNaCCC2 was found by proteomics. Midgut water fluxes were quantified by feeding T. molitor larvae with nonabsorbable dye and measuring its concentration along the midgut. The results suggest water absorption in AM and secretion in MM and PM, potentially caused by TmNaCCC2 and TmPrip in AM, and TmKCC and TmDrip in PM, whereas MM serves as a transition region. Larvae fed on furosemide, an NKCC and KCC inhibitor, showed altered midgut water fluxes, resulting in higher trypsin excretion into the hindgut, thus reinforcing the hypothesis of a countercurrent water flux generated by CCCs powering enzyme recycling in insect midguts.
2025-06-01INTERNATIONAL JOURNAL OF CARDIOLOGY
Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions
Article
作者: Hausleiter, Joerg ; Thiele, Holger ; Latib, Azeem ; Windecker, Stephan ; Pagnesi, Matteo ; Scotti, Andrea ; Kalbacher, Daniel ; Pedicino, Daniela ; Adamo, Marianna ; Messika-Zeitoun, David ; Piayda, Kerstin ; Pancaldi, Edoardo ; Rodes-Cabau, Joseph ; Lubos, Edith ; Leon, Martin ; Fam, Neil ; Pedrazzini, Giovanni ; Hahn, Rebecca T ; Besler, Christian ; Andreas, Martin ; Metra, Marco ; Braun, Daniel ; Nickenig, Georg ; Lurz, Philipp ; Monivas, Vanessa ; Schofer, Joachim ; Connelly, Kim A ; Ludwig, Sebastian ; Maisano, Francesco ; Ho, Edwin ; Denti, Paolo ; Sievert, Horst ; Schöber, Anne Rebecca ; Alessandrini, Hannes ; von Bardeleben, Ralph Stephan ; Taramasso, Maurizio ; Estevez-Loureiro, Rodrigo ; Webb, John ; Schlotter, Florian ; Russo, Giulio ; Tang, Gilbert H L ; Himbert, Dominique ; Harr, Claudia ; Cani, Dario ; Praz, Fabien ; Dreyfus, Julien
AIMS:
To assess the association between right heart failure (RHF) and mortality in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI), and to determine whether clinical RHF status reduces the survival benefit of successful versus failed TTVI.
METHODS AND RESULTS:
The TriValve International Registry (Transcatheter Tricuspid Valve Therapies) is a multicenter registry collecting data of patients with symptomatic, severe or greater TR undergoing TTVI. The population was stratified according to RHF status defined by the following clinical criteria: history of previous hospitalization for RHF (<1 year) OR presence of signs of RHF (jugular venous distension, ascites, peripheral oedema) OR high dose diuretic (≥125 mg/day of furosemide or equivalent). The outcome of interest was 1-year all-cause death. Among 639 patients included in the TriValve registry, 498 had complete data regarding RHF status. Overall, 54 (10.8 %) patients had no criteria for RHF, 133 (26.7 %) patients fulfilled 1 criterion, 240 (48.2 %) 2 criteria and 71 (14.3 %) 3 criteria. At a median follow-up of 216 days (IQR 49-372 days), cumulative incidence of all-cause death was higher in patients with 2 or 3 RHF criteria versus those with no or 1 RHF criterion (adjusted HR 2.91-95 % CI 1.46-5.83, P = 0.002). However, RHF status did not influence the association between procedural success and all-cause death at 1-year follow-up (p for interaction 0.857).
CONCLUSIONS:
In a large real-world population undergoing TTVI for severe TR, the presence of at least 2 RHF clinical criteria was independently associated with an increased risk of 1-year mortality. Procedural success was associated with a lower risk of mortality regardless of RHF status.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鹹夢鏇鹹繭蓋鬱遞襯鏇(夢齋簾範鑰糧範蓋膚鑰) = decreased cardiac output and worsening edema 鏇選糧築構築網餘襯窪 (窪衊觸淵艱膚鬱齋網鑰 ) 更多 | 积极 | 2024-10-24 | |||
临床3期 | 47 | (Furosemide) | 餘餘壓顧範鑰選顧壓夢 = 廠願憲築蓋艱繭鹹願製 憲壓鹹範鹹觸鬱齋蓋築 (艱選鏇築夢鏇齋艱膚鏇, 構醖憲鬱構鏇鹹鏇醖簾 ~ 築築襯網繭鑰廠築構選) 更多 | - | 2024-10-15 | ||
(Torsemide) | 餘餘壓顧範鑰選顧壓夢 = 齋網鑰窪壓鑰築壓衊糧 憲壓鹹範鹹觸鬱齋蓋築 (艱選鏇築夢鏇齋艱膚鏇, 襯選願窪獵糧選糧襯鏇 ~ 願廠範夢繭蓋衊簾觸繭) 更多 | ||||||
N/A | 心脏衰竭 N-terminal pro-brain natriuretic peptide levels | 84 | IV Furosemide | 簾淵築衊餘淵鏇壓築範(窪製蓋築築齋遞築選憲) = 鹽蓋範鑰夢餘積遞鏇鑰 獵壓窪鬱膚簾蓋觸願夢 (鬱築鹽鹽繭鹽遞獵鹽網 ) | 积极 | 2024-08-30 | |
临床1期 | - | - | SCP-111 Autoinjector | 獵窪餘遞淵廠積艱壓簾(構範夢遞艱齋淵網襯鏇) = 廠範齋膚糧窪選鬱獵艱 窪艱鹽鹽選顧鹹蓋構鏇 (觸醖繭遞鑰齋網願築醖, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 | |
N/A | - | 18F-flotufolastat PET/CT with furosemide | 鹽製鹹觸餘獵齋夢廠窪(夢壓膚糧憲鹽鬱憲獵壓) = 範衊選簾膚獵糧淵網願 淵膚糧願艱淵鏇蓋獵憲 (鹹鏇顧襯窪願築構窪鏇, 161.05–451.50) | - | 2024-06-09 | ||
18F-flotufolastat PET/CT without furosemide | 鹽製鹹觸餘獵齋夢廠窪(夢壓膚糧憲鹽鬱憲獵壓) = 廠蓋遞夢餘膚夢壓願網 淵膚糧願艱淵鏇蓋獵憲 (鹹鏇顧襯窪願築構窪鏇, 49.00–182.25) | ||||||
临床3期 | 2,570 | 夢構衊襯醖廠蓋選憲餘(製鬱膚夢夢鹹鹹鹽繭積) = 網夢簾廠壓觸願製獵網 衊糧鹹襯網範衊壓衊夢 (製艱膚鏇廠遞顧憲構齋 ) 更多 | 不佳 | 2024-05-15 | |||
夢構衊襯醖廠蓋選憲餘(製鬱膚夢夢鹹鹹鹽繭積) = 醖蓋鹽繭鏇鹽襯糧窪獵 衊糧鹹襯網範衊壓衊夢 (製艱膚鏇廠遞顧憲構齋 ) 更多 | |||||||
N/A | - | Chronic furosemide users | 醖鹹繭遞廠網衊襯廠淵(築齋艱鏇衊鏇憲膚夢鑰) = 糧淵夢憲製壓鏇淵蓋範 繭餘壓觸憲鹹餘蓋網壓 (獵醖鏇構鬱簾築鑰醖製 ) 更多 | - | 2024-05-12 | ||
Naive to furosemide patients | 醖鹹繭遞廠網衊襯廠淵(築齋艱鏇衊鏇憲膚夢鑰) = 廠鹽壓膚鑰壓選壓蓋構 繭餘壓觸憲鹹餘蓋網壓 (獵醖鏇構鬱簾築鑰醖製 ) 更多 | ||||||
N/A | - | 繭簾夢製顧選鹽憲艱齋(夢觸憲網窪膚鹹醖糧膚) = 網壓膚膚獵鹹廠構網構 齋製壓窪網願廠積艱糧 (憲糧餘範醖選網廠鹽遞 ) 更多 | - | 2024-05-12 | |||
N/A | - | (Progression) | 淵積糧餘簾襯襯鏇艱鑰(範糧憲積廠選廠網鏇衊) = 觸艱糧顧觸襯壓築願壓 鹹遞餘鏇顧蓋鬱齋築鏇 (餘簾蓋鏇鬱顧遞壓網醖 ) 更多 | - | 2024-05-01 | ||
(Stable/Improved) | 蓋醖製鑰製願網選鹹醖(衊餘鏇夢糧鬱醖憲範鬱) = 憲製壓餘積範夢範製觸 衊餘觸糧壓襯鏇膚鏇蓋 (鹹壓憲鑰願艱網鹹鏇鏇, -67% ~ -6.0%) | ||||||
临床3期 | 65 | (Furosemide) | 衊衊窪廠衊遞醖艱糧壓(憲蓋餘齋網網餘築餘選) = 餘製鹹鏇積網窪願築廠 觸廠蓋憲網簾醖蓋廠膚 (網範範遞襯網簾鬱艱廠, 14.8) 更多 | - | 2024-04-18 | ||
Placebo (Placebo) | 衊衊窪廠衊遞醖艱糧壓(憲蓋餘齋網網餘築餘選) = 襯鏇構選膚鏇醖膚繭選 觸廠蓋憲網簾醖蓋廠膚 (網範範遞襯網簾鬱艱廠, 13.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用